A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Celgene
Study ID
NCT06232707
Phase
PHASE3
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Alnuctamab — DRUG
    Specified dose on specified days
  • Pomalidomide — DRUG
    Specified dose on specified days
  • Daratumumab — DRUG
    Specified dose on specified days
  • Elotuzumab — DRUG
    Specified dose on specified days
  • Carfilzomib — DRUG
    Specified dose on specified days
  • Dexamethasone — DRUG
    Specified dose on specified days

Study Details

The purpose of this study is to evaluate the efficacy and safety of alnuctamab compared to standard of care regimens in participants with relapsed or refractory multiple myeloma (RRMM).

Key Dates

Start date
May 3, 2024
Status verified
May 2024
Primary completion
Nov 16, 2025
Completion
Sep 21, 2030

Study Design

Enrollment
0 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A: Alnuctamab
  • Active Comparator: Arm B: Standard of Care Regimens

Primary Outcome Measure

Progression-free Survival (PFS) [ Time Frame: Up to 5 years ]

Locations (22)

FacilityCityStateZIPSite coordinators
Local Institution - 0151BirminghamAlabama35294-
Local Institution - 0088Los AngelesCalifornia90095-
Local Institution - 0358StanfordCalifornia94305-
Local Institution - 0355New HavenConnecticut06520-
Local Institution - 0434Washington D.C.District of Columbia20007-
Local Institution - 0433WichitaKansas67214-
Local Institution - 0439Saint MatthewsKentucky40207-
Local Institution - 0323New OrleansLouisiana70112-
Local Institution - 0324BaltimoreMaryland21218-
Local Institution - 0441BethesdaMaryland20889-
Local Institution - 0435BillingsMontana59102-
Local Institution - 0157HackensackNew Jersey07601-
Local Institution - 0359SummitNew Jersey07901-
Local Institution - 0430Lake SuccessNew York11042-
Local Institution - 0396New YorkNew York10065-
Local Institution - 0306CincinnatiOhio45220-
Local Institution - 0199ClevelandOhio44109-
Local Institution - 0437PittsburghPennsylvania15224-
Local Institution - 0352ProvidenceRhode Island02903-
Local Institution - 0420WatertownSouth Dakota57201-
Local Institution - 0168DallasTexas75390-88520-
Local Institution - 0405SeattleWashington98109-

Find similar trials in Birmingham, AL

By condition
Multiple myeloma
By specialty
OncologyBlood cancer
By research site
Local Institution - 0151· Birmingham, ALLocal Institution - 0088· Los Angeles, CALocal Institution - 0358· Stanford, CALocal Institution - 0355· New Haven, CTLocal Institution - 0434· Washington D.C., DCLocal Institution - 0433· Wichita, KS

Related Studies